A Comprehensive List of US Healthcare Startups That Raised $100M+ in 2024

2024 has been a turning point for the healthtech sector. 

Despite the ongoing market challenges, investments are stabilizing, and innovative solutions—especially in artificial intelligence (AI)—are driving growth. 

According to the 2024 Future of Healthtech Report from Silicon Valley Bank (SVB), healthtech investments are now surpassing pre-pandemic levels, with $4.0 to $4.5 billion raised each quarter. 

Seed rounds are on the rise, making up 42% of total deals, compared to 21% in 2019. 

AI-focused startups alone raised $4.8 billion this year, signaling that the future of healthcare is being shaped by cutting-edge technology. 

Here are the U.S.-based healthcare and healthtech startups that raised $100 million or more so far in 2024:

October

• Maven Clinic – Funding Raised: $125 Million | Valuation: $1.7 Billion

Maven Clinic, a women’s healthcare startup, raised $125 million in its latest funding round, bringing its total funding to over $425 million. Founded in 2014, Maven offers clinical support for preconception, pregnancy, parenting, and menopause. With over 2,000 clients across 175 countries, Maven partners with employers and health plans to provide accessible healthcare for women.

• Triveni Bio – Funding Raised: $115 Million (Series B)

Triveni Bio, a biotech company focused on antibody treatments for immunological and inflammatory (I&I) disorders, raised $115 million in Series B funding. The round was led by Goldman Sachs Alternatives, with participation from Fidelity Management & Research, Deep Track Capital, and existing investors. The funds will help expand Triveni's therapeutic pipeline aimed at addressing significant healthcare needs in the I&I space.

• Glooko – Funding Raised: $100 Million (Series F)

Glooko, a digital platform for managing chronic conditions like diabetes, raised $100 million in Series F funding. The round was led by Georgian, with additional investments from Health Catalyst Capital and Canaan. This will help expand its product offerings, including data insights and device integrations. Glooko also appointed Mike Alvarez as CEO. Previously, the company raised $30 million in Series D funding in 2021.

September

• Zing Health – Funding Raised: $140 Million

Zing Health, a Medicare Advantage insurer focused on chronic special needs plans, raised $140 million in a recent funding round. The investment was led by Health 2047 Capital Partners, CRG, and First Trust Capital Partners, with support from existing investors like Newlight Partners and Town Hall Ventures. Founded in 2019, Zing Health serves nearly 13,000 members, with 62% enrolled in C-SNPs.

• Aktis Oncology – Funding Raised: $175 Million (Series B)

Aktis Oncology, a clinical-stage biotech firm specializing in targeted alpha radiopharmaceuticals for cancer treatment, secured $175 million in an oversubscribed Series B financing. The round was led by RA Capital Management, with co-leads RTW Investments and Janus Henderson Investors. Based in Boston, Aktis Oncology aims to advance its pipeline of innovative cancer therapies targeting solid tumors with this new funding. 

August

• Devoted Health – Funding Raised: $112 Million (Series E)

Devoted Health, a tech-driven Medicare Advantage provider based in Waltham, MA, secured an additional $112 million in Series E funding. This round, backed by The Space Between, Cox Enterprises, and White Road Capital, will support the company's expansion into seven new states. With a total post-money valuation of $12.87 billion, this round caps off a year of impressive funding for the company, which also raised a $1.15 billion Series D round in 2021. Devoted Health was founded in 2017 by brothers Todd and Ed Park.

July

• Spring Health – Funding Raised: $100 Million (Series E)

Spring Health raised $100 million in Series E funding, boosting its valuation to $3.3 billion. Led by Generation Investment Management, this round will help expand global access to mental healthcare. The company’s AI-powered platform now serves over 10 million lives across 400 employers and strategic payer partnerships, improving access to mental health services through 10,000+ providers.

• Spring Health – Funding Raised: $100 Million (Series E)

Spring Health has secured $100 million in Series E funding, increasing its valuation to $3.3 billion. The round was led by Generation Investment Management, with participation from Kinnevik, William K. Warren Foundation, RRE, and Northzone. Since its founding eight years ago, Spring Health has expanded its employer benefit program to cover over 10 million lives across 400 employers. Using AI, the company enhances the speed and effectiveness of mental health care, connecting users to a network of over 10,000 providers for faster access to support.

June

• AKASA – Funding Raised: $120 Million (Series C)

AKASA, a provider of AI solutions for the healthcare revenue cycle, has raised $120 million in its Series C round, bringing its total funding to $205 million. Based in San Francisco, AKASA’s platform focuses on automating revenue cycle management, addressing challenges like rising volumes and staffing shortages. Investors such as Andreessen Horowitz, Costanoa Ventures, and Bond supported the round. The funds will help AKASA enhance its AI-driven platform, which integrates cutting-edge technology with expert revenue cycle management to tackle pressing healthcare finance issues.

• Formation Bio – Funding Raised: $372 Million (Series D)

Formation Bio, an AI-native pharma company, has secured $372 million in Series D funding, led by a16z with support from Sanofi and other major investors like Sequoia and Thrive. This financing will fuel the expansion of its AI-driven drug development platform and the growth of its drug pipeline. Formation Bio is leveraging AI to automate workflows, such as generating patient recruitment content and adverse event reports in record time. These advancements reflect its commitment to innovation in both drug development and operational efficiency.

May

• Karius – Funding Raised: $100 Million (Series C)

Karius, a leader in genomic diagnostics for infectious diseases, has raised $100 million in Series C funding. The round was co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, with participation from existing investors such as Softbank Vision Fund 2 and General Catalyst. This funding will help Karius expand its reach beyond the 400 U.S. hospitals currently using the Karius Test. The test leverages genomic analysis and AI to detect over 1,000 pathogens from a single blood sample, revolutionizing the approach to infectious disease diagnostics.

• Transcarent – Funding Raised: $126 Million (Series D)

Transcarent secured $126 million in Series D funding, raising its valuation to $2.2 billion with $450 million in total funding. Led by General Catalyst and 7wireVentures, the round includes new investors like Geodesic Capital. The funds will enhance AI-driven features, support growth, and advance Transcarent’s mission to simplify and lower healthcare costs.

• Aetion – Funding Raised: $110 Million (Series C)

Aetion, a real-world evidence platform analyzing data to evaluate medical products, secured $110 million in Series C funding led by Warburg Pincus. This round doubles its lifetime funding to $212 million. The funding will enhance Aetion’s platform, grow its commercial team, and expand its presence in Europe and Asia-Pacific. Known for its partnership with the FDA during COVID-19, Aetion continues to drive innovation in healthcare analytics.

April

• Xaira Therapeutics – Funding Raised: $1 Billion

Xaira Therapeutics, headquartered in the San Francisco Bay Area, launched with a record-breaking $1 billion funding commitment, the largest initial investment ever by Arch Venture Partners. The biotech startup combines cutting-edge AI with insights from functional genomics and proteomics to pioneer transformative drug discovery.

• NexHealth – Funding Raised: $125 Million (Series C)

NexHealth, a leading patient experience platform based in the San Francisco Bay Area, raised $125 million in a Series C funding round, valuing the company at $1 billion. The round was led by Buckley Ventures, with participation from notable investors such as Lachy Groom, Jack Altman, and Packy McCormick. The funding supports NexHealth’s mission to enhance patient experiences, streamline administrative tasks for providers, and develop a universal API for healthcare developers to create innovative solutions.

March

• Mirador Therapeutics – Funding Raised: $400 Million

Mirador Therapeutics raised over $400 million, led by ARCH Venture Partners with contributions from OrbiMed and Fairmount. The biotech company, founded by Mark McKenna (ex-CEO of Prometheus Biosciences), is focused on precision therapies for immune-mediated inflammatory and fibrotic diseases. Its proprietary Mirador360 platform enables precise diagnostics and patient stratification for efficient clinical development.

• Zephyr AI – Funding Raised: $111 Million (Series A)

Zephyr AI has secured $111 million in Series A funding to further enhance its AI solutions for precision medicine. The round was led by Revolution Growth, with participation from Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group. The new capital will support Zephyr AI in accelerating its analytical capabilities and expanding its collection of training and validation data sets to better democratize precision medicine.

February

• Abridge – Funding Raised: $150 Million (Series C)

Abridge, a startup specializing in AI-powered clinical documentation tools, has raised $150 million in a Series C funding round, bringing its valuation to $850 million. The round was led by Lightspeed Venture Partners and Redpoint Ventures, following a valuation jump from over $200 million in its last funding round just four months ago. Abridge automates clinical notes and medical conversations for doctors, streamlining the documentation process and improving efficiency in healthcare settings.

• Freenome – Funding Raised: $254 Million

Freenome, a biotechnology company focused on blood tests for early cancer detection, has raised $254 million in new funding from both new and existing investors. The company is advancing its pipeline of early detection tests for colorectal and lung cancers, leveraging its multiomics platform. Freenome is currently conducting registration studies for these tests as it aims to improve early diagnosis through innovative, non-invasive technologies. The valuation at which the funds were raised has not been disclosed.

January

• Cour Pharmaceuticals – Funding Raised: $105 Million

Cour Pharmaceuticals, a Chicago-based biotech company focused on developing treatments for autoimmune diseases, has closed a $105 million funding round. The investment was co-led by Lumira Ventures and Alpha Wave Ventures, with participation from prominent investors such as Roche Venture Fund, Pfizer's Breakthrough Growth Initiative, Bristol Myers Squibb, Angelini Ventures, and the JDRF T1D Fund. 

• OnCusp Therapeutics – Funding Raised: $100 Million (Series A)

OnCusp Therapeutics has successfully raised $100 million in an oversubscribed Series A round, bringing its total funding since its establishment in 2021 to $139 million. The financing was led by Novo Holdings, OrbiMed, and F-Prime Capital, with additional participation from both new and existing investors. The funds will be used to advance OnCusp's portfolio of assets aimed at improving cancer treatments for patients.

• Lykos – Funding Raised: $100 Million (Series A)

Lykos, a California-based company specializing in MDMA therapy for PTSD, has raised $100 million in Series A funding. This investment will help the company advance its efforts to gain FDA approval for its ecstasy-based therapy. The funding supports Lykos' goal to contribute to the growing field of psychedelic-assisted therapy, including initiatives from MAPS (Multidisciplinary Association for Psychedelic Studies).

Major Healthcare Challenges These Startups Are Tackling

Healthcare startups are addressing some of the most pressing issues in the industry today. 

A major challenge is improving patient care. Traditional healthcare systems often suffer from inefficiencies and delays, but startups are using technology to streamline processes. By offering personalized care, faster diagnoses, and more accessible treatment, they’re making healthcare better for patients.

Another challenge is the rising cost of healthcare. As costs continue to climb, patients and providers alike feel the pressure. Many startups are focusing on reducing these costs by leveraging telemedicine, AI, and automation. These solutions make healthcare more affordable without compromising on quality.

Data privacy is also a big concern, especially with sensitive health information being shared and stored digitally. Startups are creating solutions to protect patient data and ensure it remains secure while still improving healthcare delivery.

By solving these challenges, these startups are paving the way for a more efficient, affordable, and secure healthcare system.

How These Startups Are Transforming the Industry: Impact on Healthcare Innovation

These healthcare startups are changing the game with innovative technology. From AI to genomics, they’re revolutionizing how we diagnose, treat, and care for patients.

Take Maven Clinic, for example. It’s not just about offering healthcare; it’s about offering it when and where women need it most. By focusing on women’s health—from preconception to menopause—Maven is redefining how care can be personalized and accessible. 

More women are getting the support they need, without the traditional barriers of waiting times and limited access.

Then there’s Spring Health. It’s tackling mental health in a big way. Using AI, Spring Health is making mental health care faster and more effective. Their platform connects employees to mental health services, reducing wait times and improving the quality of care. 

This is especially important as mental health continues to be a top concern across industries.

These startups aren’t just innovating with technology. They're transforming traditional healthcare delivery models. They're not waiting for the system to catch up—they're leading the way. 

What Are the Key Trends in Health Tech Investments?

In 2023, health tech startups secured $25 billion in VC funding, proving it’s a top investment sector, despite a 35% drop from 2021.

Key areas getting attention include telemedicine, AI, and wearables:

• Telemedicine: Remote consultations and virtual health platforms are gaining traction, making healthcare more accessible. Companies like Babylon are leading the way.

• AI in Healthcare: AI is revolutionizing diagnostics and personalized treatment. In 2023, AI healthcare companies raised $7.2 billion and $4.8 billion this year.

• Wearable Tech: Devices that track health metrics are growing in popularity. With AI integration, they’re improving chronic condition management and early disease detection.

These trends highlight the ongoing transformation in healthcare through innovation and investment.

Future Trends in Healthcare Startups: What’s Next?

The future of healthcare startups looks promising with many exciting opportunities. Here’s a quick look at what’s ahead:

• AI Investments Will Keep Growing: AI in healthcare is here to stay. Startups focusing on AI for administrative tasks like virtual assistants and note-taking are getting major attention. Clinical AI, especially in diagnostics, will also see more funding.

• Data Platforms Are Key: Startups that use AI to analyze healthcare data will continue to thrive. These solutions help with everything from improving efficiency to supporting value-based care.

• Tech-Driven Biotech: We’ll see more startups blending tech and biotech. Technologies like CRISPR and mRNA will lead to new therapies and diagnostics.

• Focus on Preventive Care: Startups focused on preventing diseases and detecting them early will attract more investment, shifting healthcare from reactive to proactive.

• Healthcare Services Innovation: Beyond tech, startups will innovate in healthcare delivery, creating new models that improve efficiency and access.

In short, healthcare startups are set for even more growth and innovation, and investors are keen to support the next big breakthrough!

How We Can Support Healthcare Startups with Tech Solutions

At SyS Creations, we specialize in providing healthcare startups with the right tech solutions to accelerate their growth. Whether you're developing AI-powered tools, building cloud infrastructure, or navigating compliance, we’ve got you covered.

• AI Development: We understand the transformative potential of AI in healthcare. Our team can help you design and implement AI solutions tailored to your specific needs, from enhancing patient care to streamlining operations. We make sure your AI applications are efficient, scalable, and, most importantly, patient-focused.

• Cloud Infrastructure: With the increasing demand for scalable, secure healthcare platforms, cloud infrastructure is crucial. We offer cloud solutions that ensure your systems are robust, flexible, and compliant with healthcare regulations, so you can focus on delivering exceptional care without worrying about tech limitations.

• Compliance Expertise: Navigating healthcare regulations like HIPAA and PIPEDA can be challenging. We provide in-depth expertise to help your startup stay compliant while focusing on innovation. Our team ensures your systems meet the highest standards of data privacy and security, so your patients’ information remains safe.

Ready to Build Your Health-Tech Platform? Let's Make It Happen!

If you're ready to develop your own health-tech platform or app, now is the perfect time. With funding on the rise, the market is primed for innovation. Our team of 50+ healthcare IT experts is here to help turn your ideas into a fully-functional, market-ready product.